Effect  	Effect  	 NN	O
of  	of  	 IN	O
benazepril  	benazepril  	 NN	B-NP
on  	on  	 IN	O
cardiac  	cardiac  	 JJ	B-NP
function  	function  	 NN	I-NP
in  	in  	 IN	O
Chinese  	Chinese  	 JJ	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
chronic  	chronic  	 JJ	B-NP
heart  	heart  	 NN	I-NP
failure 	failure 	 NN	I-NP
:  	:  	 :	O
a  	a  	 DT	O
meta-analysis  	meta-analysis  	 JJ	B-NP
of  	of  	 IN	I-NP
randomized  	randomized  	 JJ	I-NP
controlled  	controlled  	 JJ	I-NP
trials  	trials  	 NNS	I-NP
To  	To  	 TO	O
evaluate  	evaluate  	 VB	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
and  	and  	 CC	O
tolerability  	tolerability  	 NN	B-NP
of  	of  	 IN	I-NP
benazepril  	benazepril  	 NN	I-NP
in  	in  	 IN	O
Chinese  	Chinese  	 JJ	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
chronic  	chronic  	 JJ	B-NP
systolic  	systolic  	 JJ	I-NP
heart  	heart  	 NN	I-NP
failure 	failure 	 NN	I-NP
.  	.  	 .	O
We  	We  	 PRP	O
searched  	searched  	 VBD	O
the  	the  	 DT	O
databases  	databases  	 NN	O
of  	of  	 IN	O
Cochrane 	Cochrane 	 NNP	O
,  	,  	 ,	O
PubMed 	PubMed 	 NNP	B-NP
,  	,  	 ,	O
EMbase 	EMbase 	 NNP	B-NP
,  	,  	 ,	O
CBM  	CBM  	 NNP	B-NP
and  	and  	 CC	O
CNKI  	CNKI  	 NNP	B-NP
from  	from  	 IN	O
January  	January  	 NNP	O
1989  	1989  	 CD	O
to  	to  	 TO	O
November  	November  	 NNP	O
2010  	2010  	 CD	O
for  	for  	 IN	O
the  	the  	 DT	O
relevant  	relevant  	 JJ	O
studies 	studies 	 NNS	O
.  	.  	 .	O
Two  	Two  	 CD	O
investigators  	investigators  	 NNS	B-NP
identified  	identified  	 VBD	O
randomized  	randomized  	 VBN	B-NP
controlled  	controlled  	 VBN	I-NP
trials  	trials  	 NNS	I-NP
( 	( 	 -LRB-	O
RCTs 	RCTs 	 NNP	B-NP
)  	)  	 -RRB-	O
independently  	independently  	 RB	O
according  	according  	 VBG	O
to  	to  	 TO	O
the  	the  	 DT	O
predefined  	predefined  	 JJ	B-NP
inclusion  	inclusion  	 NN	I-NP
and  	and  	 CC	O
exclusion  	exclusion  	 NN	B-NP
criteria 	criteria 	 NNS	I-NP
.  	.  	 .	O
Statistical  	Statistical  	 JJ	B-NP
data  	data  	 NN	I-NP
analysis  	analysis  	 NN	I-NP
was  	was  	 VBD	O
performed  	performed  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
Stata  	Stata  	 NNP	B-NP
11  	11  	 CD	O
software 	software 	 NN	O
.  	.  	 .	O
A  	A  	 DT	O
total  	total  	 NN	O
of  	of  	 IN	O
15  	15  	 CD	O
studies  	studies  	 NNS	O
with  	with  	 IN	O
1  	1  	 CD	O
355  	355  	 CD	O
Chinese  	Chinese  	 JJ	O
patients  	patients  	 NNS	O
of  	of  	 IN	O
chronic  	chronic  	 JJ	B-NP
systolic  	systolic  	 JJ	I-NP
heart  	heart  	 NN	I-NP
failure  	failure  	 NN	I-NP
fulfilled  	fulfilled  	 VBD	O
the  	the  	 DT	O
inclusion  	inclusion  	 NN	B-NP
criteria 	criteria 	 NNS	I-NP
.  	.  	 .	O
Among  	Among  	 IN	O
them 	them 	 PRP	O
,  	,  	 ,	O
546  	546  	 CD	O
received  	received  	 VBD	O
benazepril  	benazepril  	 JJ	B-NP
monotherapy 	monotherapy 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
dose  	dose  	 NN	O
range  	range  	 NN	O
of  	of  	 IN	O
benazepril  	benazepril  	 NN	B-NP
was  	was  	 VBD	O
5  	5  	 CD	O
to  	to  	 TO	O
40  	40  	 CD	O
mg  	mg  	 CD	B-NP
daily 	daily 	 JJ	O
.  	.  	 .	O
And  	And  	 CC	O
it  	it  	 PRP	O
was  	was  	 VBD	O
similar  	similar  	 JJ	O
to  	to  	 TO	O
angiotensin  	angiotensin  	 VB	B-NP
II  	II  	 NNP	I-NP
receptor  	receptor  	 FW	I-NP
blockers  	blockers  	 FW	I-NP
( 	( 	 -LRB-	O
ARBs 	ARBs 	 NNP	B-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
improving  	improving  	 VBG	O
left  	left  	 VBN	B-NP
ventricular  	ventricular  	 JJ	I-NP
ejection  	ejection  	 JJ	I-NP
fraction  	fraction  	 NN	I-NP
( 	( 	 -LRB-	O
LVEF 	LVEF 	 NNP	B-NP
) 	) 	 -RRB-	O
( 	( 	 -LRB-	O
P  	P  	 NN	O
=  	=  	 SYM	O
0.674 	0.674 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
reducing  	reducing  	 VBG	B-NP
LVEDD  	LVEDD  	 NNP	I-NP
( 	( 	 -LRB-	O
P  	P  	 NN	O
=  	=  	 SYM	O
0.511 	0.511 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
improving  	improving  	 VBG	O
cardiac  	cardiac  	 JJ	B-NP
output  	output  	 NN	I-NP
( 	( 	 -LRB-	O
P  	P  	 NN	O
=  	=  	 SYM	O
0.363 	0.363 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
combination  	combination  	 NN	B-NP
therapy  	therapy  	 NN	I-NP
of  	of  	 IN	I-NP
benazepril  	benazepril  	 NN	I-NP
and  	and  	 CC	O
ARB  	ARB  	 NNP	B-NP
was  	was  	 VBD	O
superior  	superior  	 JJ	O
to  	to  	 TO	O
ARB  	ARB  	 NNP	B-NP
monotherapy  	monotherapy  	 NN	I-NP
in  	in  	 IN	O
reducing  	reducing  	 VBG	O
left  	left  	 VBN	B-NP
ventricular  	ventricular  	 JJ	I-NP
end-diastolic  	end-diastolic  	 JJ	I-NP
diameter  	diameter  	 NNS	I-NP
( 	( 	 -LRB-	O
LVEDD 	LVEDD 	 NNP	B-NP
)  	)  	 -RRB-	O
( 	( 	 -LRB-	O
P  	P  	 NN	O
=  	=  	 SYM	O
0.001 	0.001 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
LVEF  	LVEF  	 NNP	B-NP
was  	was  	 VBD	O
comparable  	comparable  	 JJ	O
between  	between  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
ACEI 	ACEI 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
ARB  	ARB  	 NNP	I-NP
combination  	combination  	 NN	I-NP
therapy  	therapy  	 NN	I-NP
and  	and  	 CC	O
those  	those  	 DT	O
with  	with  	 IN	O
ARB  	ARB  	 NNP	B-NP
monotherapy  	monotherapy  	 NNS	I-NP
( 	( 	 -LRB-	O
P  	P  	 NN	O
=  	=  	 SYM	O
0.105 	0.105 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Compared  	Compared  	 VBN	O
with  	with  	 IN	O
blank  	blank  	 JJ	O
control 	control 	 NN	O
,  	,  	 ,	O
benazepril  	benazepril  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
was  	was  	 VBD	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
significant  	significant  	 JJ	O
improvement  	improvement  	 NN	O
in  	in  	 IN	O
LVEF  	LVEF  	 NNP	B-NP
from  	from  	 IN	O
baseline  	baseline  	 NN	B-NP
to  	to  	 TO	O
follow-up  	follow-up  	 NNP	O
( 	( 	 -LRB-	O
WMD  	WMD  	 NNP	B-NP
=  	=  	 SYM	O
6.5 	6.5 	 CD	O
% 	% 	 NN	O
;  	;  	 :	O
95 	95 	 CD	O
%  	%  	 NN	O
CI 	CI 	 NNP	O
:  	:  	 :	O
0.9 	0.9 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
12.0 	12.0 	 CD	O
% 	% 	 NN	O
;  	;  	 :	O
P  	P  	 NN	O
=  	=  	 SYM	O
0.022 	0.022 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Compared  	Compared  	 VBN	O
with  	with  	 IN	O
baseline 	baseline 	 NN	B-NP
,  	,  	 ,	O
benazepril  	benazepril  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
significantly  	significantly  	 RB	O
increased  	increased  	 VBN	B-NP
LVEF  	LVEF  	 NNP	I-NP
( 	( 	 -LRB-	O
WMD  	WMD  	 NNP	B-NP
=  	=  	 SYM	O
10.4 	10.4 	 CD	O
% 	% 	 NN	O
;  	;  	 :	O
95 	95 	 CD	O
%  	%  	 NN	O
confidence  	confidence  	 NN	B-NP
interval  	interval  	 NNS	I-NP
[ 	[ 	 -LRB-	O
CI 	CI 	 NNP	O
] 	] 	 -RRB-	O
: 	: 	 :	O
7.1 	7.1 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
13.8 	13.8 	 CD	O
% 	% 	 NN	O
;  	;  	 :	O
P  	P  	 NNP	O
< 	< 	 SYM	O
0.001 	0.001 	 NNP	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
cardiac  	cardiac  	 JJ	B-NP
output  	output  	 NN	I-NP
( 	( 	 -LRB-	O
WMD  	WMD  	 NNP	B-NP
=  	=  	 SYM	O
1.5  	1.5  	 CD	O
L 	L 	 NNP	O
;  	;  	 :	O
CI 	CI 	 NNP	O
: 	: 	 :	O
0.3 	0.3 	 CD	O
,  	,  	 ,	O
2.6  	2.6  	 CD	O
L 	L 	 NNP	O
,  	,  	 ,	O
P  	P  	 NN	O
=  	=  	 SYM	O
0.016 	0.016 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
A  	A  	 DT	O
significant  	significant  	 JJ	O
reduction  	reduction  	 NN	O
in  	in  	 IN	O
LVEDD  	LVEDD  	 NNP	B-NP
( 	( 	 -LRB-	O
WMD  	WMD  	 NNP	B-NP
=  	=  	 SYM	O
5.3  	5.3  	 CD	O
mm 	mm 	 NNS	O
;  	;  	 :	O
CI 	CI 	 NNP	O
:  	:  	 :	O
2.7 	2.7 	 CD	O
,  	,  	 ,	O
7.8  	7.8  	 CD	O
mm 	mm 	 NN	O
,  	,  	 ,	O
P  	P  	 NNP	O
< 	< 	 SYM	O
0.001 	0.001 	 NNP	O
)  	)  	 -RRB-	O
was  	was  	 VBD	O
also  	also  	 RB	O
observed  	observed  	 VBN	O
in  	in  	 IN	O
benazepril  	benazepril  	 JJ	B-NP
group 	group 	 NN	I-NP
.  	.  	 .	O
As  	As  	 IN	O
the  	the  	 DT	O
most  	most  	 RBS	O
common  	common  	 JJ	O
side  	side  	 NN	B-NP
effect  	effect  	 NN	I-NP
after  	after  	 IN	O
benazepril  	benazepril  	 JJ	B-NP
treatment 	treatment 	 NN	I-NP
,  	,  	 ,	O
cough  	cough  	 NN	O
had  	had  	 VBD	O
a  	a  	 DT	O
prevalence  	prevalence  	 NN	O
of  	of  	 IN	O
11.6 	11.6 	 CD	O
% 	% 	 NN	O
.  	.  	 .	O
Other  	Other  	 JJ	O
side  	side  	 NN	O
effects  	effects  	 NNS	O
were  	were  	 VBD	O
rare 	rare 	 JJ	O
.  	.  	 .	O
Benazepril  	Benazepril  	 NNP	B-NP
is  	is  	 VBZ	O
both  	both  	 DT	O
efficacious  	efficacious  	 NN	O
and  	and  	 CC	O
safe  	safe  	 JJ	O
in  	in  	 IN	O
the  	the  	 DT	O
management  	management  	 NN	O
of  	of  	 IN	O
Chinese  	Chinese  	 JJ	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
chronic  	chronic  	 JJ	B-NP
heart  	heart  	 NN	I-NP
failure 	failure 	 NN	I-NP
.  	.  	 .	O
